Search results

Skip to results

Type

Status

Last updated

Showing 1 to 4 of 4 results for letermovir

  1. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus disease after a stem cell transplant.

    Technology appraisal guidance
    Published
    31 July 2019
    View recommendations

    Sections for TA591

  2. Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) (TA1082)

    NICE is unable to make a recommendation on letermovir (Prevymis) for preventing cytomegalovirus infection after a kidney transplant in adults. This is because the company did not provide an evidence submission.

    Technology appraisal guidance
    Published
    23 July 2025

    Sections for TA1082

  3. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant [TS ID 11868]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

    Technology appraisal guidance
    Published
    18 January 2023
    View recommendations

    Sections for TA860